NCT04187547 is a Phase 3 clinical trial of Tricaprilin in Alzheimer's Disease, sponsored by Cerecin.

Who is sponsoring NCT04187547?

NCT04187547 is sponsored by Cerecin.

What drugs are being tested in NCT04187547?

Interventions in NCT04187547: Tricaprilin, Placebo.

What condition does NCT04187547 study?

NCT04187547 studies Alzheimer's Disease.

Is NCT04187547 still recruiting?

NCT04187547 is currently withdrawn. Last updated 14 April 2023.

Last reviewed 2023-04-14 · How we verify

NCT04187547

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase III Multi Regional Clinical Trial (MRCT) of Tricaprilin in Mild to Moderately Severe Probable Alzheimer's Disease With Optional Open Label Extension

Withdrawn Phase 3 Last updated 14 April 2023

What this trial tests

Phase 3 trial testing Tricaprilin in Alzheimer's Disease. Withdrawn.

Timeline

30 June 2022

Primary endpoint
31 December 2023

28 February 2024

Quick facts

Lead sponsor	Cerecin
Phase	Phase 3
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Start date	30 June 2022
Primary completion	31 December 2023
Estimated completion	28 February 2024

Drugs / interventions tested

Tricaprilin — full drug profile →
Placebo

Conditions studied

Alzheimer's Disease — all drugs for Alzheimer's Disease →

Sponsor

Cerecin — full company profile →

Who can join

Adults 50 to 90, any sex, with Alzheimer's Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is Phase 3 study, multi-centre, double-blind, placebo controlled, parallel group to evaluate the effects of AC-SD-03 on the efficacy and safety among participants with mild to moderate Alzheimer's Disease.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Alzheimer's disease drug development pipeline: 2022.
Cummings J, Lee G, Nahed P, Kambar MEZN, et al · · 2022 · cited 369× · PMID 35516416 · DOI 10.1002/trc2.12295
Alzheimer's disease drug development pipeline: 2020.
Cummings J, Lee G, Ritter A, Sabbagh M, et al · · 2020 · cited 350× · PMID 32695874 · DOI 10.1002/trc2.12050
Alzheimer's disease drug development pipeline: 2023.
Cummings J, Zhou Y, Lee G, Zhong K, et al · · 2023 · cited 326× · PMID 37251912 · DOI 10.1002/trc2.12385
Alzheimer's disease drug development pipeline: 2021.
Cummings J, Lee G, Zhong K, Fonseca J, et al · · 2021 · cited 312× · PMID 34095440 · DOI 10.1002/trc2.12179
Pathological mechanisms and therapeutic strategies for Alzheimer's disease.
Ju Y, Tam KY. · · 2022 · cited 260× · PMID 34380884 · DOI 10.4103/1673-5374.320970
Astrocytes as Key Regulators of Brain Energy Metabolism: New Therapeutic Perspectives.
Beard E, Lengacher S, Dias S, Magistretti PJ, et al · · 2021 · cited 186× · PMID 35087428 · DOI 10.3389/fphys.2021.825816
Clinical trials of new drugs for Alzheimer disease: a 2020-2023 update.
Huang LK, Kuan YC, Lin HW, Hu CJ. · · 2023 · cited 165× · PMID 37784171 · DOI 10.1186/s12929-023-00976-6
Glutamate and GABA in Microglia-Neuron Cross-Talk in Alzheimer's Disease.
Czapski GA, Strosznajder JB. · · 2021 · cited 125× · PMID 34769106 · DOI 10.3390/ijms222111677

Verify or expand the search:

Other trials of Tricaprilin

Trials testing the same drug.

NCT04727970 — Tricaprilin Infantile Spasms Pilot Study · Phase 1 · completed
NCT04437199 — Tricaprilin Phase 2 Pilot Study in Migraine · Phase 2 · completed
NCT04268953 — Study to Compare the Pharmacokinetics of Daily Administration of Tricaprilin on Ketone Body Production · Phase 1 · completed
NCT03971123 — Study to Compare the Pharmacokinetics of Tricaprilin Formulations and a Placebo on Ketone Body Production · Phase 1 · completed
NCT03628352 — Taste-masking Study for Tricaprilin in Sensory Panelists · Phase 1 · completed

Other recruiting trials for Alzheimer's Disease

Currently open trials in the same condition.

NCT07457138 — Lombard Cohort of Brain Health Services · recruiting
NCT07234942 — A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants Wit · Phase 1 · recruiting
NCT07479914 — Art of Memory for Cognitive Enhancement in the Monza Brain Health Service · NA · active not recruiting
NCT07214727 — A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease · Phase 1 · recruiting
NCT07105709 — Open-label Extension Study in Participants With Early Alzheimer's Disease · Phase 2 · recruiting

Other Cerecin trials

Trials by the same sponsor.

NCT05628636 — AC-OLE-01-VA Tolerability Study in Healthy Participants Under Different Dosing Conditions · Phase 1 · completed
NCT05408780 — A Phase 1, Two-part, Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Liquid Formulation · Phase 1 · completed
NCT04727970 — Tricaprilin Infantile Spasms Pilot Study · Phase 1 · completed
NCT05028114 — Tricaprilin Liquid Formulation PK Study · Phase 1 · terminated
NCT04437199 — Tricaprilin Phase 2 Pilot Study in Migraine · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04187547 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cerecin
Last refreshed: 14 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04187547.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing